MAU-868 is a monoclonal antibody commercialized by Vera Therapeutics, with a leading Phase II program in Polyomavirus Infections. According to Globaldata, it is involved in 3 clinical trials, of which 2 were completed, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of MAU-868’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for MAU-868 is expected to reach an annual total of $4 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

MAU-868 Overview

MAU-868 is under development for the treatment and prevention of BK virus associated nephropathy and hemorrhagic cystitis. The drug candidate is a human monoclonal antibody (immunoglobulin G, IgG1) which is formulated as a solution and administered as an infusion via intravenous route. It acts by targeting major viral capsid protein of BKV, VP1.

Vera Therapeutics Overview

Vera Therapeutics is a biotechnology company that discovers and develops treatments for immunological diseases. It is investigating its lead product candidate Atacicept, a recombinant self-administered fusion protein to treat IgA nephropathy (IgAN) and lupus nephritis (LN). The company is also evaluating MAU868, a neutralizing antibody targeting BK viremia in renal transplant recipients and BKV cystitis in hematopoietic stem cell transplant (HSCT) recipients. Its product candidate targets B cells and plasma cells and reduces disease causing autoantibodies. Vera Therapeutics is headquartered in Brisbane, California, the US.

The operating loss of the company was US$31.7 million in FY2021, compared to an operating loss of US$52.2 million in FY2020. The net loss of the company was US$32.6 million in FY2021, compared to a net loss of US$53.4 million in FY2020.

For a complete picture of MAU-868’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.